Acute Effects of High Intensity Training in Pregnancy on Fetal Well-being and Blood Flow Distribution (HITFLOW)

Acute Effects of HIT on Fetal Well-being and Blood Flow Distribution - a Pilot Study

Pregnant women are recommended to be physically active ≥150 min/week, but <15% of Norwegian women attain this goal. Several well-designed studies on lifestyle interventions focusing primarily on exercise training in overweight/obese pregnant women have reported disappointing outcomes with regard to maternal glycemic control, gestational weight gain and infant outcomes. Low adherence to the training program was found to be a problem; the participants did not enjoy the exercise program and had difficulties scheduling time to exercise. Pregnant women also report that they are not sure what exercises are safe during pregnancy.

High intensity interval training (HIT), defined as short periods of intense activity separated by low-intensity breaks, has proved to induce superior improvements in insulin sensitivity and fitness compared with continuous moderate intensity training in individuals at increased risk for cardiometabolic diseases. Even short-term (6 weeks) HIT with brief (15-60 sec) work-bouts and a total time commitment of <45 min per week, improves insulin sensitivity similar to that attained after 6 months of traditional endurance training.

HIT is feasible and enjoyable for individuals with low fitness level and with obesity.

HIT is therefore a highly potent intervention that elicits important changes in a range of clinically relevant health outcomes in reproductive-aged women.

This study will investigate fetal responses to a single bout of HIT. Preliminary data of the investigators suggest that HIT does not negatively influence fetal heart rate. Others have reported that uterine and umbilical blood flow are not changed during or following acute exercise. However, no previous study has determined the acute effect of HIT on uterine blood flow and there are no studies investigating the fetal blood flow distribution in response to exercise. Since the relative distribution of blood to the fetal liver is associated with newborn adiposity, fetal blood flow distribution in response to exercise can provide insight about the effect of maternal exercise on offspring health.

Study Overview

Status

Recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Trondheim, Norway
        • Recruiting
        • Dept Circulation and Medical Imaging, EXCAR Exercise Lab
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • pregnant, gestational week 22-36
  • singleton fetus
  • no known diseases
  • capable of cycling on an ergometer bike

Exclusion Criteria:

  • hypertension
  • gestational diabetes mellitus
  • any contraindication to exercise training

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Doing a single HIT session in gestational week 22-36
10 minutes warming up at low-to-moderate intensity, 8x30 seconds high intensity interval training with fetal heart rate measurement after each 30 second work-bout, 2 minutes recovery at low-to-moderate intensity. Continuous monitoring of maternal heart rate.
Other Names:
  • HIT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
blood flow in fetal veins
Time Frame: 1 day
examined by Doppler ultrasound during 30 minutes
1 day
blood flow in fetal arteries
Time Frame: 1 day
examined by Doppler ultrasound during 30 minutes
1 day

Secondary Outcome Measures

Outcome Measure
Time Frame
maternal heart rate
Time Frame: 1 dag
1 dag
Fetal heart rate
Time Frame: 1 day
1 day
Umbilical vein diameter
Time Frame: 1 day
1 day
Maternal systolic blood pressure
Time Frame: 1 day
1 day
Maternal diastolic blood pressure
Time Frame: 1 day
1 day
Maternal body weight
Time Frame: 1 day
1 day
Maternal height
Time Frame: 1 day
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Director: Kjell Å Salvesen, md prof, St Olavs Hospital, Dept of Obstetrics and Gynecology
  • Principal Investigator: Trine Moholdt, phd, Norwegian University of Science and Technology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 23, 2022

Primary Completion (Estimated)

January 1, 2025

Study Completion (Estimated)

February 1, 2025

Study Registration Dates

First Submitted

February 26, 2020

First Submitted That Met QC Criteria

February 26, 2020

First Posted (Actual)

February 28, 2020

Study Record Updates

Last Update Posted (Actual)

April 3, 2024

Last Update Submitted That Met QC Criteria

April 2, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy

Clinical Trials on Single high-intensity interval training session

3
Subscribe